Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 262.00M | 258.00M | 117.00M | 112.00M | 383.00M | 78.00M |
Gross Profit | 262.00M | 258.00M | 117.00M | 112.00M | 383.00M | 78.00M |
EBITDA | -282.00M | -269.00M | -291.00M | -258.00M | 59.00M | -120.00M |
Net Income | -306.00M | -283.00M | -307.00M | -267.00M | 53.00M | -123.00M |
Balance Sheet | ||||||
Total Assets | 1.07B | 1.15B | 1.09B | 1.34B | 1.59B | 772.29M |
Cash, Cash Equivalents and Short-Term Investments | 911.00M | 978.00M | 759.00M | 1.14B | 681.30M | 735.09M |
Total Debt | 109.00M | 60.00M | 11.00M | 120.00M | 116.89M | 15.24M |
Total Liabilities | 526.00M | 665.00M | 633.00M | 688.00M | 750.45M | 269.99M |
Stockholders Equity | 549.00M | 485.00M | 462.00M | 657.00M | 841.45M | 502.30M |
Cash Flow | ||||||
Free Cash Flow | -342.00M | -176.00M | -330.00M | 426.00M | -282.25M | 108.11M |
Operating Cash Flow | -339.00M | -170.00M | -306.00M | 438.00M | -256.17M | 111.17M |
Investing Cash Flow | 191.00M | -84.00M | 194.00M | -413.00M | -3.87M | -434.37M |
Financing Cash Flow | 240.00M | 277.00M | 33.00M | 33.00M | 237.34M | 438.68M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $814.27M | ― | -43.63% | ― | ― | -13.05% | |
54 Neutral | $1.15B | ― | -50.34% | ― | 6.07% | -2.28% | |
52 Neutral | ― | ― | 271.44% | 26.65% | |||
51 Neutral | $7.91B | -0.36 | -41.70% | 2.23% | 23.45% | -1.86% | |
43 Neutral | $1.00B | 2.31 | -41.00% | ― | ― | -429.68% | |
42 Neutral | $460.53M | ― | -73.44% | ― | ― | -1.07% | |
33 Underperform | $734.71M | ― | -109.12% | ― | ― | 7.58% |
On June 10, 2025, Arcus Biosciences held its annual meeting of stockholders, where key proposals were voted on, including the election of Class I directors and the ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025. Additionally, the Board of Directors revised the Non-Employee Director Compensation Program, reflecting the company’s ongoing efforts to align its governance and compensation practices with industry standards.